Member Info for Brand

I recall searching for papers and studies on INFb vs Covid only a few months ago and it was generally slim pickings - now there is so much out there I can barely keep up.

Interferon and interferon-stimulated genes are the bêtes noires of SARS-CoV-2. So much so that deficiencies in interferon production and action are a major cause of serious disease and death following SARS-CoV-2 infection. Patients who have failed to make interferon or who have antibodies that neutralize interferon are overrepresented in hospitalized patients in need of intensive care, as are people who inherit deficiencies in many of the signaling proteins outlined in Figure 2. Therefore, it should come as no surprise that SARS-CoV-2 encodes numerous proteins that interfere with interferon synthesis.

https://www.genengnews.com/topics/translational-medicine/infectious-diseases/beating-covid-19-means-tipping-the-balance-of-an-age-old-struggle-part-ii/

'This is a pilot trial requested by regulators to validate the additional questions that are included in SG018 which determine the OSCI score when patients have been discharged from hospital. The study is proceeding on time and as it is an independent study, will not delay the SPRINTER study (SG018).'

https://clinicaltrials.gov/ct2/show/NCT05207293

Like in a previous study [14], the presence of neutralizing auto-Abs is associated with a more frequent mortality. Up to 21% of patients who died of COVID-19 pneumonia in our study had auto-Abs capable of neutralizing 100 pg/mL type I IFNs in plasma 1/10. Deceased patients with auto-Abs did not present overt clinical differences with deceased patients without auto-Abs. These results confirm importance of the IFN-I pathway in the defense against SARS-CoV-2 infection.
https://link.springer.com/article/10.1007/s10875-021-01203-3

'IFN-I (mainly including IFNa and IFNß) is a key player among antiviral actions early during the infection. In 1957, Isaacs and Lindenman discovered IFN-I which demonstrated a natural and rapid antiviral activity. IFN-I works on the host cells as autocrine and paracrine factors to induce the expression of various IFN-stimulated genes (ISGs) to promote cellular antiviral activity. IFN-I is also a bridge linking the innate with adaptive immune systems [4]. When the virus infects the cells, IFN-1 normally immediately induces strong local reactions to trigger the production of proteins by the infected cells to attack the virus, while also recruiting immune cells to the infection site and notifying adjacent cells to prepare for defense and battle [4]. Therefore, the normal functioning of IFN-1 directly affects COVID-19 progression. IFN-1 deficiency may result in life-threatening viral infections. Why would the function of IFN-1 fail during COVID-19 infections? How can we provide treatment targeting IFN-1 malfunction? These are key issues in COVID-19 treatment.'

https://www.sciencedirect.com/science/article/pii/S2667325822000474

https://clinicaltrials.gov/ct2/show/NCT05207293

The publishing of the SNG019 trial make this the most likely answer:

4. the results are so good they re applying for EUA and will rns both news at same time

'early 2022' even....

Not speculating on these particular trades, but it's worth noting that trades in SYGGF appear on LSE as 'Unknown'

Just FYI: Trades on SYGGF appear on LSE as 'Unknown'

FTC7 given you spend most of your time on here telling other people they are wrong, feel it's only right to point out that was an exceptionally poorly judged comment....

Between parliament/boris and transfer deadline day it would have been a poor choice to do today. Need to make a lot of noise locally to get the message out globally

Could well be one to frame!

My first thought when I saw the content of this morning's RNS was that it was a great way to stress test the new mailing list/company notifications service...

Think this is the one....

https://link.springer.com/article/10.1007/s10875-021-01203-3

I think the RNS comes (whenever it comes) w commercial news and still sticking to my £20+ prediction, valuing the company at £4-5B

The email alerting service worked this time.

Fair play mate. This is my only investment so spend a fair amount of time here...

Reads pretty well!

Design, develop and implement Synairgen’s logistics operations globally. The role is responsible for overseeing, supporting and managing supply chain logistics strategy and execution operations in order to maximise process efficiency, sustainability and productivity. The role requires an in-depth understanding of pharmaceutical supply chain and logistics operations and is responsible to ensure Synairgen’s global network will always be able to support the strategic vision of the company including a focus on short and long term launches and expansions.

Ah. Yes it was well discussed at length by some of the most distinguished members of this board. Understand poly ramped up their buying in the days after it would to appear to have passed. If you scroll far enough back you should be able to find it. Example of this board at its best tbh.